Skip to main content

Metagenomi Therapeutics, Inc. (MGX) research

Metagenomi Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$1.12
As of

Metagenomi Therapeutics, Inc. (MGX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.

As of . Source: SEC EDGAR filings for MGX. Method and limitations.

SHARE THIS CARD

Share the MGX intelligence card

A branded snapshot of MGX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion MGX intelligence card preview
Post to X
LIVE TERMINAL

See MGX live in the terminal

Track MGX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live MGX terminal, free

Active signals for MGX

FREE, NO ACCOUNT

Every signal on MGX, as it fires

You are seeing 5 of 8 signals recorded on MGX since 2026-06-03.

The five above landed across 4 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in MGX (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 59102M104 · 2026Q2$883K0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 59102M104 · 2026Q2$611K0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 59102M104 · 2026Q2$136K0.00%,
CITADEL ADVISORS LLCCUSIP 59102M104 · 2026Q2$21K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, MGX

MGX against its peers

MGX's operating margin of -380.9% ranks in the 65th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.

MetricMGXPeer medianPercentilen
Revenue FY25.2M USD500000 USD7111
Operating margin-380.9%-8021.4%659
Net margin-348.5%-633.9%5910
Return on equity-55.4%-109.8%7517

Peers (21): ATNM, ANVS, MREO, KPTI, ATYR, VERU, GRCE, CELU, HOWL, TVGN, EDSA, IMMP, CRVO, IBO, TIL, ELTX, MCRB, HRTX, FLNA, GNTA, ELOX. Left out: BETRF (period gap), LITS (no annual filing), SEOVF (no annual filing), HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (MGX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more MGX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MGXand get the insider, 13F, options, and confluence read in one view.

Open the live MGX terminal, free